GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRI Bio, Inc., a US-based clinical-stage biotech company, announced it received a Notice of Allowance from the UAE Patent Office for novel type 2 diverse NKT cell agonists designed to treat inflammatory conditions. This patent strengthens the company's global intellectual property portfolio and supports its immunomodulatory platform focused on infl…